Analysts Issue Forecasts for Natera Inc’s Q2 2020 Earnings (NASDAQ:NTRA)

Natera Inc (NASDAQ:NTRA) – Investment analysts at Piper Sandler issued their Q2 2020 earnings estimates for shares of Natera in a note issued to investors on Tuesday, June 9th. Piper Sandler analyst S. Mah expects that the medical research company will post earnings per share of ($0.51) for the quarter. Piper Sandler currently has a “Overweight” rating and a $56.00 target price on the stock. Piper Sandler also issued estimates for Natera’s Q3 2020 earnings at ($0.54) EPS, Q4 2020 earnings at ($0.55) EPS, FY2020 earnings at ($2.05) EPS, Q1 2021 earnings at ($0.43) EPS, Q2 2021 earnings at ($0.42) EPS, Q3 2021 earnings at ($0.36) EPS, Q4 2021 earnings at ($0.29) EPS and FY2021 earnings at ($1.50) EPS.

Several other analysts have also commented on NTRA. Canaccord Genuity boosted their price target on Natera from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Zacks Investment Research lowered Natera from a “buy” rating to a “hold” rating in a research note on Thursday. ValuEngine raised Natera from a “hold” rating to a “buy” rating in a research note on Wednesday, March 18th. Cowen boosted their price target on Natera from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Finally, JPMorgan Chase & Co. raised Natera from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $32.00 to $45.00 in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $45.56.

Shares of NTRA stock opened at $42.38 on Friday. The stock’s fifty day simple moving average is $41.75 and its 200 day simple moving average is $35.94. The company has a quick ratio of 2.73, a current ratio of 2.81 and a debt-to-equity ratio of 0.38. Natera has a one year low of $16.87 and a one year high of $49.22.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported ($0.45) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.12. The business had revenue of $94.01 million for the quarter, compared to analyst estimates of $85.02 million. Natera had a negative return on equity of 78.56% and a negative net margin of 38.28%. Natera’s quarterly revenue was up 40.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.54) EPS.

In other news, CTO Jonathan Sheena sold 7,885 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $49.05, for a total transaction of $386,759.25. Following the completion of the sale, the chief technology officer now owns 249,969 shares in the company, valued at $12,260,979.45. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Gail Boxer Marcus sold 7,278 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $45.99, for a total value of $334,715.22. Following the sale, the director now owns 497 shares of the company’s stock, valued at approximately $22,857.03. The disclosure for this sale can be found here. In the last three months, insiders sold 191,858 shares of company stock worth $8,022,602. Insiders own 9.29% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of Natera by 0.9% during the fourth quarter. FMR LLC now owns 3,690,471 shares of the medical research company’s stock worth $124,332,000 after acquiring an additional 31,298 shares during the last quarter. Orbimed Advisors LLC raised its position in shares of Natera by 37.1% during the first quarter. Orbimed Advisors LLC now owns 3,347,000 shares of the medical research company’s stock worth $99,941,000 after acquiring an additional 906,387 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Natera by 42.0% during the first quarter. Wells Fargo & Company MN now owns 2,946,307 shares of the medical research company’s stock worth $87,977,000 after acquiring an additional 870,916 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Natera by 120.9% during the first quarter. JPMorgan Chase & Co. now owns 2,876,779 shares of the medical research company’s stock worth $85,901,000 after acquiring an additional 1,574,662 shares during the last quarter. Finally, State Street Corp raised its position in shares of Natera by 1.9% during the first quarter. State Street Corp now owns 2,538,454 shares of the medical research company’s stock worth $75,798,000 after acquiring an additional 47,857 shares during the last quarter. Institutional investors own 93.91% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also: Are FAANG stocks a good investment?

Earnings History and Estimates for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.